You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 654 Real world incidence of grade III and higher adverse effects, emergency room utilization and hospital admissions during treatment with commonly used PD-1/PDL-1 targeting immune check point inhibitors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Immunotherapy toxicities
654 Real world incidence of grade III and higher adverse effects, emergency room utilization and hospital admissions during treatment with commonly used PD-1/PDL-1 targeting immune check point inhibitors

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020100010
Dec 20204206
Jan 20214404
Feb 20211001
Mar 202132010
Apr 20213005
May 2021804
Jun 20210013
Jul 2021002
Aug 2021005
Sep 2021005
Oct 202124021
Nov 20218013
Dec 20211000
Jan 20221403
Feb 20221003
Mar 2022802
Apr 20223603
May 20221601
Jun 20221801
Jul 2022802
Aug 20221803
Sep 20222001
Oct 20221400
Nov 2022800
Dec 20221201
Jan 20231400
Feb 20232601
Mar 20231402
Apr 20232601
May 20231401
Jun 20231401
Jul 2023804
Aug 2023602
Sep 20232202
Oct 20233003
Nov 20232403
Dec 20232800
Jan 20241801
Feb 20243000
Mar 20241600
Apr 20242801
May 20243002
Jun 20243000
Jul 20241201
Aug 20241201
Sep 20241201
Oct 20241206
Nov 2024803
Dec 2024604
Jan 20251207
Feb 2025202
Mar 2025007
Apr 2025005
May 2025003
Jun 2025002
Total9440185